Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy

Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy

Murine-based CD19 CAR-T (CD19m CAR-T) therapy can lead to a relatively high CR rate when administered to B-ALL patients for the first time. However, the DOR is sub-optimal and a subset of patients even show primary resistance to CD19m CAR-T. To address these issues, we employed a humanized selective...

Full description

Bibliographic Details
Main Authors: Yu Zhao, Jianping Zhang, Junfang Yang, Huantong Wu, Yao Chen, Nannan Li, Zhongfeng Liu, Xuan Wang, Weihua Liu, Guangji Zhang, Bin-Bing Stephen Zhou, Peihua Lu, Zhiguo Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
CAR-T
humanized
repeated dosing
selective domain
B-ALL
HSCT
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.884782/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.884782/full

Similar Items